ES2662380T3 - Método para detectar nucleosomas que contienen variantes de histonas - Google Patents
Método para detectar nucleosomas que contienen variantes de histonas Download PDFInfo
- Publication number
- ES2662380T3 ES2662380T3 ES12762367.6T ES12762367T ES2662380T3 ES 2662380 T3 ES2662380 T3 ES 2662380T3 ES 12762367 T ES12762367 T ES 12762367T ES 2662380 T3 ES2662380 T3 ES 2662380T3
- Authority
- ES
- Spain
- Prior art keywords
- histone
- nucleosomes
- body fluid
- nucleosome
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001623 nucleosome Anatomy 0.000 title claims abstract description 370
- 108010047956 Nucleosomes Proteins 0.000 title claims abstract description 369
- 108010033040 Histones Proteins 0.000 title claims abstract description 261
- 238000000034 method Methods 0.000 title claims description 201
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 108
- 239000000090 biomarker Substances 0.000 claims abstract description 98
- 201000011510 cancer Diseases 0.000 claims abstract description 85
- 108010029485 Protein Isoforms Proteins 0.000 claims abstract description 78
- 102000001708 Protein Isoforms Human genes 0.000 claims abstract description 78
- 210000001124 body fluid Anatomy 0.000 claims abstract description 69
- 239000010839 body fluid Substances 0.000 claims abstract description 69
- 238000003745 diagnosis Methods 0.000 claims abstract description 12
- 210000002381 plasma Anatomy 0.000 claims description 83
- 210000002966 serum Anatomy 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 45
- 230000027455 binding Effects 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 29
- 239000011230 binding agent Substances 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000002429 large intestine Anatomy 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 210000000664 rectum Anatomy 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 70
- 238000001514 detection method Methods 0.000 description 66
- 201000010099 disease Diseases 0.000 description 60
- 108020004414 DNA Proteins 0.000 description 50
- 102100023919 Histone H2A.Z Human genes 0.000 description 45
- 101000905054 Homo sapiens Histone H2A.Z Proteins 0.000 description 45
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Nonanedioid acid Natural products OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 44
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 41
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 239000002773 nucleotide Substances 0.000 description 31
- 238000003556 assay Methods 0.000 description 30
- 238000012360 testing method Methods 0.000 description 29
- 102000006947 Histones Human genes 0.000 description 28
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 25
- 230000007067 DNA methylation Effects 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000003018 immunoassay Methods 0.000 description 22
- 239000003446 ligand Substances 0.000 description 22
- 238000005259 measurement Methods 0.000 description 20
- 108010077544 Chromatin Proteins 0.000 description 18
- 230000002583 anti-histone Effects 0.000 description 18
- 210000003483 chromatin Anatomy 0.000 description 18
- 238000012544 monitoring process Methods 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 15
- 201000005202 lung cancer Diseases 0.000 description 15
- 208000020816 lung neoplasm Diseases 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000011002 quantification Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 239000012472 biological sample Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 208000003445 Mouth Neoplasms Diseases 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 9
- 210000003040 circulating cell Anatomy 0.000 description 9
- 238000002405 diagnostic procedure Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 9
- 230000011987 methylation Effects 0.000 description 9
- 238000007069 methylation reaction Methods 0.000 description 9
- 201000002528 pancreatic cancer Diseases 0.000 description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 description 9
- 239000013060 biological fluid Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 238000004393 prognosis Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000011534 wash buffer Substances 0.000 description 8
- 102100039869 Histone H2B type F-S Human genes 0.000 description 7
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002967 competitive immunoassay Methods 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 238000003748 differential diagnosis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000013198 immunometric assay Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 102100030670 Core histone macro-H2A.2 Human genes 0.000 description 4
- 101710185000 Core histone macro-H2A.2 Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 230000003447 ipsilateral effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 108091029523 CpG island Proteins 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091029430 CpG site Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 230000006429 DNA hypomethylation Effects 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108010022894 Euchromatin Proteins 0.000 description 2
- 108010034791 Heterochromatin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108050002584 Septin 9 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000000632 euchromatin Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004458 heterochromatin Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010034959 macroH2A histone Proteins 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- ZALMSPFXLKMWDY-GMJFWCJPSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(1-hydroxyethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1[C@H](O)[C@@H](C(O)C)O[C@H]1N1C(=O)N=C(N)C=C1 ZALMSPFXLKMWDY-GMJFWCJPSA-N 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 101100450031 Caenorhabditis elegans htz-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101001084710 Drosophila melanogaster Histone H2A.v Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102100024739 E3 ubiquitin-protein ligase UHRF1 Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 101710166728 Histone H3 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000760417 Homo sapiens E3 ubiquitin-protein ligase UHRF1 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 102000012060 Septin 9 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 238000001093 holography Methods 0.000 description 1
- 238000007031 hydroxymethylation reaction Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005296 lymph node development Effects 0.000 description 1
- 208000010949 lymph node disease Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530304P | 2011-09-01 | 2011-09-01 | |
| GBGB1115098.4A GB201115098D0 (en) | 2011-09-01 | 2011-09-01 | Method for detecting nucleosomes containing histone variants |
| GB201115098 | 2011-09-01 | ||
| US201161530304P | 2011-09-01 | ||
| PCT/GB2012/052131 WO2013030579A1 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing histone variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2662380T3 true ES2662380T3 (es) | 2018-04-06 |
Family
ID=44882049
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12762367.6T Active ES2662380T3 (es) | 2011-09-01 | 2012-08-31 | Método para detectar nucleosomas que contienen variantes de histonas |
| ES17201723T Active ES2955475T3 (es) | 2011-09-01 | 2012-08-31 | Método para detectar nucleosomas que contienen variantes de histonas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17201723T Active ES2955475T3 (es) | 2011-09-01 | 2012-08-31 | Método para detectar nucleosomas que contienen variantes de histonas |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US9400276B2 (enExample) |
| EP (2) | EP2751569B1 (enExample) |
| JP (2) | JP2014529405A (enExample) |
| KR (1) | KR102130855B1 (enExample) |
| CN (2) | CN108107215A (enExample) |
| AU (1) | AU2012300643B2 (enExample) |
| BR (1) | BR112014004584B1 (enExample) |
| CA (1) | CA2845994C (enExample) |
| DK (1) | DK2751569T3 (enExample) |
| ES (2) | ES2662380T3 (enExample) |
| GB (1) | GB201115098D0 (enExample) |
| HR (1) | HRP20180362T1 (enExample) |
| HU (1) | HUE038517T2 (enExample) |
| MX (1) | MX349561B (enExample) |
| PL (1) | PL2751569T3 (enExample) |
| PT (1) | PT2751569T (enExample) |
| RU (2) | RU2716494C2 (enExample) |
| SG (2) | SG11201400202SA (enExample) |
| WO (1) | WO2013030579A1 (enExample) |
| ZA (1) | ZA201401296B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115098D0 (en) | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| GB201115095D0 (en) * | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| ES2693349T3 (es) | 2012-06-06 | 2018-12-11 | The Trustees Of Princeton University | Aplicación de códigos de barras de ADN de bancos de matrices de cromatinas y mononucleosomas diseñadores para la creación de perfiles de lectores, escritores, borradores y moduladores de cromatina de los mismos |
| EP3597774A1 (en) | 2013-03-13 | 2020-01-22 | Sequenom, Inc. | Primers for dna methylation analysis |
| EP3117011B1 (en) | 2014-03-13 | 2020-05-06 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CN107209190B (zh) | 2014-10-29 | 2021-07-16 | 比利时意志有限责任公司 | 用于富集循环肿瘤dna的方法 |
| CN107250799B (zh) * | 2015-02-10 | 2019-09-10 | B.R.A.H.M.S 有限公司 | 作为生物标志物的游离组蛋白 |
| GB201511542D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell free nucleosomes as biomarkers |
| GB201511512D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell-free nucleosomes as biomarkers |
| GB201518674D0 (en) * | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for detecting nuleosomes containing histone modifications and variants |
| GB201518665D0 (en) * | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for enrichment of cell free nucleosomes |
| GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
| GB201612815D0 (en) * | 2016-07-25 | 2016-09-07 | Belgian Volition Sa | Novel combination test |
| TWI726009B (zh) * | 2016-11-28 | 2021-05-01 | 比利時商比利時意志有限公司 | 用親和純化法分析生物樣品中源自腫瘤之無細胞核小體、分離生物樣品中純化之腫瘤dna、檢測生物樣品中源自腫瘤之核小體表觀遺傳表位或在動物或人類受試者中檢測癌症之方法或包括組蛋白h1結合劑之套組之用途 |
| JP7228514B2 (ja) | 2016-12-09 | 2023-02-24 | ザ・ブロード・インスティテュート・インコーポレイテッド | Ｃｒｉｓｐｒエフェクターシステムベースの診断法 |
| BR112019019087A2 (pt) | 2017-03-15 | 2020-05-12 | The Broad Institute, Inc. | Diagnóstico baseado em sistema efetor de crispr para detecção de vírus |
| GB201721569D0 (en) | 2017-12-21 | 2018-02-07 | Belgian Volition Sprl | Method for the detection and treatment of colorectal adenomas |
| CA3087362A1 (en) | 2018-01-29 | 2019-08-01 | The Broad Institute, Inc. | Crispr effector system based diagnostics |
| DK3759249T3 (da) | 2018-03-01 | 2023-10-30 | Epicypher Inc | Kvantificering af nukleosommodifikationer ved anvendelse af kemisk definerede rekombinante nukleosomer |
| WO2019195268A2 (en) | 2018-04-02 | 2019-10-10 | Grail, Inc. | Methylation markers and targeted methylation probe panels |
| AU2019351130B2 (en) | 2018-09-27 | 2025-10-23 | GRAIL, Inc | Methylation markers and targeted methylation probe panel |
| GB201818963D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Methof for the detection of prostate cancer |
| GB201818965D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Method for the detection of colorectal cancer |
| GB201906199D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
| GB201906201D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Voltion Sprl | Method for the detection of protate cancer |
| GB201912251D0 (en) | 2019-08-27 | 2019-10-09 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
| AU2020336928A1 (en) | 2019-08-27 | 2022-03-24 | Belgian Volition Srl | Method of isolating circulating nucleosomes |
| ES2988371T3 (es) | 2019-12-02 | 2024-11-20 | Belgian Volition Srl | Uso de nucleosomas libres de células como biomarcadores |
| WO2021186037A1 (en) | 2020-03-20 | 2021-09-23 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
| EP4213909A1 (en) | 2020-09-21 | 2023-07-26 | Belgian Volition SRL | Device for inline monitoring of free nucleosomes in blood |
| TW202238131A (zh) | 2020-11-25 | 2022-10-01 | 比利時商比利時意志有限公司 | 測量無細胞核蛋白染色質片段之方法 |
| TW202238132A (zh) | 2020-12-08 | 2022-10-01 | 比利時商比利時意志有限公司 | 多發性硬化症之診斷方法 |
| TW202242145A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析 |
| TW202242130A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 循環轉錄因子分析 |
| TW202242146A (zh) | 2021-01-13 | 2022-11-01 | 比利時商比利時意志有限公司 | 肺癌的檢測方法 |
| GB202108185D0 (en) | 2021-06-08 | 2021-07-21 | Belgian Volition Sprl | Standardisation of nucleosome assays using biologically derived calibrants |
| GB202108452D0 (en) | 2021-06-14 | 2021-07-28 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
| US20250012783A1 (en) | 2021-10-29 | 2025-01-09 | Belgian Volition Srl | Homogeneous immunoassay method |
| GB202117799D0 (en) | 2021-12-09 | 2022-01-26 | Belgian Volition Srl | Method for the detection of blood cancer |
| EP4490323A1 (en) | 2022-03-11 | 2025-01-15 | Belgian Volition SRL | Differential diagnosis method |
| GB202205212D0 (en) | 2022-04-08 | 2022-05-25 | Belgian Volition Sprl | Method for transplant organ health assessment |
| WO2024042210A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for measuring cell free chromatin |
| WO2024042208A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for the detection of dementia |
| WO2024133222A1 (en) | 2022-12-19 | 2024-06-27 | Belgian Volition Srl | Assessment of biological samples for nucleic acid analysis |
| EP4639173A1 (en) | 2022-12-19 | 2025-10-29 | Belgian Volition SRL | Calibration |
| GB202300607D0 (en) | 2023-01-16 | 2023-03-01 | Belgian Volition Srl | Proteins and methods for isolating circulating nucleosomes |
| GB202303562D0 (en) | 2023-03-10 | 2023-04-26 | Belgian Volition Sprl | Sample collection for liquid biopsy |
| WO2024213795A1 (en) | 2023-04-14 | 2024-10-17 | Belgian Volition Srl | Diagnosis method using cell free nucleosome levels |
| WO2024223947A1 (en) | 2023-04-28 | 2024-10-31 | Belgian Volition Srl | Use of cell free nucleosomes as biomarkers of carcinomas |
| GB202307768D0 (en) | 2023-05-24 | 2023-07-05 | Belgian Volition Srl | Use of cell free nucleosomes as biomarkers |
| GB202310137D0 (en) | 2023-07-03 | 2023-08-16 | Belgian Volition Srl | Method for the detection of cancer |
| WO2025012440A1 (en) | 2023-07-13 | 2025-01-16 | Belgian Volition Srl | Method for detection of the potential of a body fluid sample to produce extracellular traps |
| WO2025061853A1 (en) | 2023-09-19 | 2025-03-27 | Belgian Volition Srl | Lateral flow test device |
| WO2025093747A1 (en) | 2023-11-02 | 2025-05-08 | Belgian Volition Srl | Novel rapid high-throughput method of netosis induction and inhibition with physiologically relevant molecules |
| WO2025181348A1 (en) | 2024-03-01 | 2025-09-04 | Belgian Volition Srl | Method for determining the origin of circulating dna |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040186274A1 (en) * | 2001-07-03 | 2004-09-23 | Allis C. David | Methylation of histone h4 at arginine 3 |
| DE10207735A1 (de) * | 2002-02-15 | 2003-08-28 | Euroimmun Gmbh | Verfahren zur Herstellung einer Nukleosomen-Präparation und deren Verwendung zur in vitro-Diagnose von Lupus erythematodes disseminatus (LED) |
| CA2476835A1 (en) | 2002-02-20 | 2003-08-28 | University Of Virginia Patent Foundation | A non-invasive diagnostic test utilizing histone modification markers |
| GB0319376D0 (en) * | 2003-08-18 | 2003-09-17 | Chroma Therapeutics Ltd | Histone modification detection |
| WO2005040814A1 (en) * | 2003-10-14 | 2005-05-06 | Cancer Research Technology Limited | Methods and means of cancer detection by histone modification |
| WO2007017065A2 (en) * | 2005-07-27 | 2007-02-15 | Oncomethylome Sciences Sa | Angiogenesis inhibition based upon icam 1 or junb expression levels |
| WO2007032876A2 (en) * | 2005-09-09 | 2007-03-22 | University Of Iowa Research Foundation | Biomarkers associated with age-related macular degeneration |
| WO2010033658A2 (en) * | 2008-09-17 | 2010-03-25 | The Rockefeller University | Cathepsin l proteolytically processes histone h3 during mouse embroyonic stem cell differentiation |
| EP2270510A1 (en) * | 2009-07-02 | 2011-01-05 | EMBL (European Molecular Biology Laboratory) | Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms |
| GB201115098D0 (en) | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
-
2011
- 2011-09-01 GB GBGB1115098.4A patent/GB201115098D0/en not_active Ceased
-
2012
- 2012-08-31 KR KR1020147008116A patent/KR102130855B1/ko active Active
- 2012-08-31 EP EP12762367.6A patent/EP2751569B1/en active Active
- 2012-08-31 PL PL12762367T patent/PL2751569T3/pl unknown
- 2012-08-31 CA CA2845994A patent/CA2845994C/en active Active
- 2012-08-31 SG SG11201400202SA patent/SG11201400202SA/en unknown
- 2012-08-31 US US14/239,779 patent/US9400276B2/en active Active
- 2012-08-31 BR BR112014004584-4A patent/BR112014004584B1/pt active IP Right Grant
- 2012-08-31 WO PCT/GB2012/052131 patent/WO2013030579A1/en not_active Ceased
- 2012-08-31 MX MX2014002444A patent/MX349561B/es active IP Right Grant
- 2012-08-31 RU RU2018101257A patent/RU2716494C2/ru active
- 2012-08-31 ES ES12762367.6T patent/ES2662380T3/es active Active
- 2012-08-31 CN CN201711384538.7A patent/CN108107215A/zh active Pending
- 2012-08-31 ES ES17201723T patent/ES2955475T3/es active Active
- 2012-08-31 CN CN201280053594.1A patent/CN104053993A/zh active Pending
- 2012-08-31 PT PT127623676T patent/PT2751569T/pt unknown
- 2012-08-31 EP EP17201723.8A patent/EP3301449B1/en active Active
- 2012-08-31 SG SG10201601168QA patent/SG10201601168QA/en unknown
- 2012-08-31 AU AU2012300643A patent/AU2012300643B2/en active Active
- 2012-08-31 JP JP2014527738A patent/JP2014529405A/ja not_active Withdrawn
- 2012-08-31 DK DK12762367.6T patent/DK2751569T3/en active
- 2012-08-31 RU RU2014112348/15A patent/RU2014112348A/ru unknown
- 2012-08-31 HR HRP20180362TT patent/HRP20180362T1/hr unknown
- 2012-08-31 HU HUE12762367A patent/HUE038517T2/hu unknown
-
2014
- 2014-02-20 ZA ZA2014/01296A patent/ZA201401296B/en unknown
-
2016
- 2016-06-22 US US15/189,977 patent/US10184945B2/en active Active
-
2017
- 2017-08-02 JP JP2017149809A patent/JP6494703B2/ja active Active
-
2018
- 2018-12-14 US US16/221,411 patent/US20190120853A1/en not_active Abandoned
-
2020
- 2020-07-09 US US16/925,125 patent/US20200341006A1/en not_active Abandoned
-
2022
- 2022-12-06 US US18/076,005 patent/US20230116530A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2662380T3 (es) | Método para detectar nucleosomas que contienen variantes de histonas | |
| ES2663603T3 (es) | Procedimiento para detectar nucleosomas | |
| ES2717659T3 (es) | Procedimiento para la detección de nucleosomas que contienen nucleótidos | |
| ES2649404T3 (es) | Procedimiento para detectar aductos de nucleosomas | |
| ES2772701T3 (es) | Uso de nucleosomas libres de células como biomarcadores en muestras de esputo | |
| US20170003296A1 (en) | Method for detecting histone modifications in nucleosomes | |
| ES2775178T3 (es) | Uso de nucleosomas libres de células como biomarcadores en muestras fecales | |
| HK1253354B (en) | Method for detecting nucleosomes containing histone variants | |
| HK1199758B (en) | Method for detecting nucleosomes containing histone variants |